分子学定义继发性急性髓系白血病中低甲基化药物联合维奈克拉与强化诱导化疗方案的比较
本研究比较395例分子学定义继发性急性髓系白血病患者的结局,分别接受柔红霉素联合阿糖胞苷(7+3,n=167)、脂质体柔红霉素联合阿糖胞苷(CPX-351,n=66)或低甲基化药物联合维奈克拉(HMA+VEN,n=162)治疗。年龄>60岁患者中各治疗组中位总生存期相当;多变量模型中HMA+VEN较7+3与更好的总生存期相关(HR 0.64,95%CI 0.42-0.98,p=0.041),而CPX-351较7+3无此关联。作者认为在分子学定义继发性急性髓系白血病中HMA+VEN可能更受青睐,但可进一步由共突变指导。
要点
- 多变量模型中HMA+VEN较7+3与更好总生存期相关(HR 0.64,95%CI 0.42-0.98,p=0.041)。
- CPX-351较7+3与总生存期无显著关联(HR 0.79,95%CI 0.50-1.25,p=0.31)。
- 作者认为HMA+VEN可能更受青睐,并可进一步由共突变指导。
核心结论
- 在分子学定义继发性急性髓系白血病中,HMA+VEN治疗可能更受青睐,但可进一步由共突变指导。
研究设计与样本
- 研究纳入395例分子学定义继发性急性髓系白血病患者,比较7+3(n=167)、CPX-351(n=66)与HMA+VEN(n=162)的结局。
主要发现
- 年龄>60岁患者中各治疗组中位总生存期相当。
- 多变量模型中HMA+VEN较7+3与更好总生存期相关(HR 0.64,95%CI 0.42-0.98,p=0.041),CPX-351较7+3无显著关联(HR 0.79,95%CI 0.50-1.25,p=0.31)。
- 异基因造血干细胞移植、BCOR和IDH突变与更好总生存期相关;年龄较大、既往髓系疾病、NRAS/KRAS突变、EZH2突变和单体核型与更差总生存期相关。
- 分别分析各治疗时,IDH共突变的获益见于7+3,NRAS/KRAS共突变的不利影响见于HMA+VEN和CPX-351。
- 年龄校正后的成对比较中,HMA+VEN较7+3在SF3B1突变患者中与更好总生存期相关,较CPX-351在RNA剪接因子突变患者中与更好总生存期相关。
关键数值与推荐
- HMA+VEN较7+3的总生存期HR 0.64(95%CI 0.42-0.98,p=0.041)。
- CPX-351较7+3的总生存期HR 0.79(95%CI 0.50-1.25,p=0.31)。
临床怎么用
- 作者认为在分子学定义继发性急性髓系白血病中HMA+VEN可能更受青睐,但可进一步由共突变指导。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Molecularly defined secondary acute myeloid leukemia is associated with a prior myeloid neoplasm and confers a worse prognosis. We compared outcomes of molecularly defined secondary AML patients (n = 395) treated with daunorubicin and cytarabine (7 + 3, n = 167), liposomal daunorubicin and cytarabine (CPX-351, n = 66) or hypomethylating agents (HMA) + venetoclax (VEN) (n = 162). Median overall survival (OS) was comparable between treatment groups among patients aged >60 years. In a multivariable model HMA + VEN vs. 7 + 3 was associated with better OS (hazard ratio [HR] 0.64 [95% confidence interval (CI) 0.42-0.98, p = 0.041]), whereas CPX-351 vs. 7 + 3 was not (HR 0.79 [CI 95% 0.50-1.25, p = 0.31]). Allogeneic hematopoietic stem cell transplantation, BCOR and IDH mutations were associated with improved OS; older age, prior myeloid disease, NRAS/KRAS mutations, EZH2 mutation, and monosomal karyotype were associated with worse OS. When analyzed in each treatment separately, the IDH co-mutations benefit was seen with 7 + 3 and the detrimental effect of NRAS/KRAS co-mutations with HMA + VEN and CPX-351. In pairwise comparisons adjusted for age, HMA + VEN was associated with improved OS vs. 7 + 3 in patients with SF3B1 mutation and improved OS vs. CPX-351 in those with RNA splicing factor mutations. In molecularly defined secondary AML treatment with HMA + VEN might be preferred but could further be guided by co-mutations.
引用
- Shimony S, Bewersdorf JP, Shallis RM, et al. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia. 2024. PMID: 38378841. doi:10.1038/s41375-024-02175-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。